These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35635108)

  • 21. Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
    Zhang Z; Lin Q; Xu Y; Guan W; Song X; Li Y; Zhang Y; Li T; Yu W
    Arch Osteoporos; 2023 Apr; 18(1):48. PubMed ID: 37041320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
    Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Glass TR; Amstutz A; Tschumi N; Belus JM; Klimkait T; Labhardt ND
    HIV Med; 2023 Feb; 24(2):153-162. PubMed ID: 35730213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
    Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM
    BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.
    Han Y; Li Y; Xie J; Qiu Z; Li Y; Song X; Zhu T; Li T
    PLoS One; 2015; 10(3):e0120705. PubMed ID: 25821963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effectiveness and safety of generic version of lamivudine/tenofovir and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2012-2014].
    Amariles P; Galindo J; Mueses-Marín HF; Castañeda C
    Rev Chilena Infectol; 2019 Feb; 36(1):32-40. PubMed ID: 31095202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
    Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
    Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
    Cuco RM; Loquiha O; Juga A; Couto A; Meggi B; Vubil A; Sevene E; Osman N; Temermam M; Degomme O; Sidat M; Bhatt N
    PLoS One; 2022; 17(2):e0261522. PubMed ID: 35143515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
    Llibre JM; Brites C; Cheng CY; Osiyemi O; Galera C; Hocqueloux L; Maggiolo F; Degen O; Taylor S; Blair E; Man C; Wynne B; Oyee J; Underwood M; Curtis L; Bontempo G; van Wyk J
    Clin Infect Dis; 2023 Feb; 76(4):720-729. PubMed ID: 35235656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
    Mendes JC; Bonolo PF; Ceccato MDGB; Costa JO; Reis AMM; Dos Santos H; Silveira MR
    Eur J Clin Pharmacol; 2018 Aug; 74(8):1077-1088. PubMed ID: 29740676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of cumulative viraemia following treatment initiation with different antiretroviral regimens: a real-life study in Brazil.
    Pascom AR; Pinho RE; Rick F; Veras NM; Perini FB; Meireles MV; Pereira GF; Benzaken AS; Avelino-Silva VI
    J Int AIDS Soc; 2019 Nov; 22(11):e25397. PubMed ID: 31743620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.
    Yilmaz A; Mellgren Å; Fuchs D; Nilsson S; Blennow K; Zetterberg H; Gisslén M
    Infect Dis (Lond); 2019; 51(11-12):838-846. PubMed ID: 31556765
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
    Guillemi SA; Ling SH; Dahlby JS; Yip B; Zhang W; Hull MW; Lima VD; Hogg RS; Werb R; Montaner JS; Harris M
    J Int AIDS Soc; 2016; 19(1):20995. PubMed ID: 27624144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluation of doravirine/tenofovir disoproxil fumarate/lamivudine for HIV-1-infected adults in Russia: a cost-minimization and budget impact analysis.
    Pyadushkina E; Derkach E; Rozenberg V; Ugrekhelidze D; Lobodina A; Baxter C; Beyer A
    Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1215-1220. PubMed ID: 36154357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
    Bangsberg DR; Ragland K; Monk A; Deeks SG
    AIDS; 2010 Nov; 24(18):2835-40. PubMed ID: 21045636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH; Chan K; Raboud J; Cooper C; Montaner JS; Walmsley S; Hogg RS; Klein MB; Machouf N; Rourke SB; Tsoukas C; Loutfy MR;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):38-46. PubMed ID: 21709570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.
    Liu P; Liao L; Xu W; Yan J; Zuo Z; Leng X; Wang J; Kan W; You Y; Xing H; Ruan Y; Shao Y
    Medicine (Baltimore); 2018 Dec; 97(50):e13555. PubMed ID: 30558015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.